The sNDA is supported by data from the phase 3 ADAURA trial that assessed osimertinib vs placebo in 682 patients with early-stage EGFRm NSCLC after complete tumor resection with or without adjuvant chemotherapy.
The MET alteration occurs in 3% to 4% of patients with the condition.
In this study, a PD-L1 expression of at least 50% in tumor or at least 10% in tumor-infiltrating immune cells was classified as high-level expression.
Brigatinib demonstrated antitumor activity among patients with progressive NSCLC with ALK alterations after treatment with other next-generation ALK TKIs.
A significant amount of progress has been made in improving the treatment of lung cancer and patient outcomes. However, a number of disparities that can have an impact on these persist, including those affecting lung cancer screening. Lung cancer screening is an essential step toward effective treatment and improved survival, but its success depends on…
PD-L1 expression density and cytotoxic T cells were identified as potential biomarkers for outcomes with ICIs in patients with NSCLC.
The addition of apatinib to gefitinib prolonged PFS compared with gefitinib among treatment-naive patients with EGFR-mutated NSCLC.
The use of modern postoperative conformal radiotherapy did not improve DFS and was associated with toxicities among patients with stage IIIAN2 NSCLC.
NGS of longitudinal samples from patients with advanced NSCLC receiving ICIs identified changes associated with hyperprogression and early death.
Overexpression of cannabinoid receptor CB2 may be a prognostic biomarker for NSCLC adenocarcinomas.
